Delta, Lambda COVID Variants Still Weighing On Market Despite Positive Earnings Reports
The market is still in a waiting mode, with a lot hinging on tomorrow’s jobs report.
Sanofi – Regeneron’s Libtayo/Chemo Treatment Improves Overall Survival First-Line Lung Cancer
The Phase 3 trial of Sanofi SA (NASDAQ:SNY) and Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) Libtayo in combination with platinum-doublet chemotherapy was stopped early after…
Regeneron Beats Street Estimates Big In Q2 As COVID-19 Antibody Boosts Topline, Cuts FY21 R&D Spend Outlook
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) earned $25.80 per share for the second quarter, beating the $17.69 estimate. It clocked revenue of…
Regeneron Pharmaceuticals: Q2 Earnings Insights
Shares of Regeneron Pharmaceuticals (NASDAQ:REGN) moved higher by 0.0% in pre-market trading after the company reported Q2 results.
Quarterly Results
Earnings per share were up 260.34% year over year to $25.80, which beat the estimate of $17.69.
Regeneron Pharmaceuticals Q2 Adj. EPS $25.80 Beats $17.69 Estimate, Sales $5.14B Beat $3.89B Estimate
Regeneron Pharmaceuticals (NASDAQ:REGN) reported quarterly earnings of $25.80 per share which beat the analyst consensus estimate of $17.69 by 45.85 percent. This is a 260.34 percent increase over earnings of $7.16 per
Regeneron Says Phase 3 Trial Of Libtayo With Chemotherapy Was Stopped Early After Meeting Overall Survival Primary Endpoint
Libtayo combined with chemotherapy increased median overall survival from 13 to 22 months, leading to a 29% reduction in the risk of death
Trial enrolled patients with locally advanced and metastatic disease
Earnings Scheduled For August 5, 2021
Companies Reporting Before The Bell
• OneSpaWorld Holdings (NASDAQ:OSW) is projected to report quarterly loss at $0.20 per share on revenue of $6.42 million.
New England Journal of Medicine Publishes Phase 3 Trial Results for REGEN-COV™ (casirivimab and imdevimab) to Prevent SARS-CoV-2 Infection
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) today announced that the New England Journal of Medicine (NEJM) published positive detailed results from a Phase 3 trial that assessed the
HC Wainwright & Co. Maintains Buy on Regeneron Pharmaceuticals, Raises Price Target to $741
HC Wainwright & Co. analyst Michael King maintains Regeneron Pharmaceuticals (NASDAQ:REGN) with a Buy and raises the price target from $729 to $741.
FDA Approves Regeneron – Roche’s COVID-19 Antibody Cocktail For Post-Exposure Prophylaxis
Following the June update that allowed for a lower dose of REGEN-COV, the FDA has again expanded emergency use authorization for the…